• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与卵巢癌筛查相关的心理疾病:来自卵巢癌筛查随机试验(英国卵巢癌筛查协作试验)中超过23000名女性的结果。

Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS).

作者信息

Barrett J, Jenkins V, Farewell V, Menon U, Jacobs I, Kilkerr J, Ryan A, Langridge C, Fallowfield L

机构信息

Cardiovascular Epidemiology Unit, Department of Public Health & Primary Care, University of Cambridge, Cambridge, UK.

出版信息

BJOG. 2014 Aug;121(9):1071-9. doi: 10.1111/1471-0528.12870. Epub 2014 May 28.

DOI:10.1111/1471-0528.12870
PMID:24865441
Abstract

OBJECTIVE

To examine the psychological sequelae associated with abnormal screening in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

DESIGN

Prospective, longitudinal randomised control trial.

SETTING

Sixteen UKCTOCS centres.

SAMPLE

Women aged 50-70 years randomised to annual multimodal screening, ultrasound screening or control groups.

METHODS

Two groups were followed for 7 years: (1) a random sample (n = 1339), taken from all three study groups; and (2) an events sample (n = 22,035) of women with abnormal screens resulting in the need for repeat testing of either low or higher level intensity.

MAIN OUTCOME MEASURES

Patient-reported measures of anxiety (scores ranging from 20 to 80) and psychological morbidity.

RESULTS

In the random sample the mean difference between anxiety scores after a repeat screening and those following an annual screening was 0.4 (95% CI -0.46, 1.27), and in the events sample it was 0.37 (95% CI 0.23, 0.51). The risk of psychological morbidity was only increased in the event sample for women requiring higher level repeat screening (OR 1.28; 95% CI 1.18, 1.39). The risk of psychological morbidity in women with ovarian cancer was higher at both 6 weeks (OR 16.2; 95% CI 9.19, 28.54) and 6 months (OR 3.32; 95% CI 1.91, 5.77) following surgery.

CONCLUSIONS

Screening does not appear to raise anxiety but psychological morbidity is elevated by more intense repeat testing following abnormal annual screens, and in women after surgical treatment for ovarian cancer.

摘要

目的

在英国卵巢癌筛查协作试验(UKCTOCS)中,研究与异常筛查相关的心理后遗症。

设计

前瞻性、纵向随机对照试验。

地点

16个UKCTOCS中心。

样本

年龄在50至70岁之间的女性,随机分为年度多模式筛查组、超声筛查组或对照组。

方法

两组随访7年:(1)从所有三个研究组中抽取的随机样本(n = 1339);(2)异常筛查结果导致需要进行低强度或高强度重复检测的女性事件样本(n = 22,035)。

主要观察指标

患者报告的焦虑测量指标(分数范围为20至80)和心理疾病发病率。

结果

在随机样本中,重复筛查后的焦虑评分与年度筛查后的焦虑评分之间的平均差异为0.4(95%可信区间-0.46, 1.27),在事件样本中为0.37(95%可信区间0.23, 0.51)。仅在事件样本中,需要进行更高水平重复筛查的女性心理疾病发病风险增加(比值比1.28;95%可信区间1.18, 1.39)。卵巢癌女性在手术后6周(比值比16.2;95%可信区间9.19, 28.54)和6个月(比值比3.32;95%可信区间1.91, 5.77)时心理疾病发病风险更高。

结论

筛查似乎不会增加焦虑,但年度筛查异常后的更密集重复检测以及卵巢癌手术治疗后的女性心理疾病发病率会升高。

相似文献

1
Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS).与卵巢癌筛查相关的心理疾病:来自卵巢癌筛查随机试验(英国卵巢癌筛查协作试验)中超过23000名女性的结果。
BJOG. 2014 Aug;121(9):1071-9. doi: 10.1111/1471-0528.12870. Epub 2014 May 28.
2
Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.普通人群卵巢癌筛查的死亡率影响、风险及益处:英国卵巢癌筛查协作试验(UKCTOCS)随机对照试验
Health Technol Assess. 2025 May;29(10):1-93. doi: 10.3310/BHBR5832.
3
Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening.在经历一次重复筛查后,与退出英国卵巢癌筛查协作试验相关的社会心理因素。
Int J Gynecol Cancer. 2015 Oct;25(8):1519-25. doi: 10.1097/IGC.0000000000000507.
4
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).多模式及超声筛查卵巢癌的敏感性和特异性,以及所检测癌症的分期分布:英国卵巢癌筛查协作试验(UKCTOCS)患病率筛查结果
Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.
5
The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT.卵巢癌筛查对性活动及性功能的影响:英国卵巢癌筛查随机对照试验协作组的研究结果
Br J Cancer. 2017 Apr 11;116(8):1111-1117. doi: 10.1038/bjc.2017.72. Epub 2017 Mar 21.
6
7
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.接受卵巢癌筛查的绝经前后高危女性:焦虑、风险认知与生活质量。
Gynecol Oncol. 2003 Jun;89(3):440-6. doi: 10.1016/s0090-8258(03)00147-1.
8
Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).美国多模式卵巢癌筛查计划的成本效益评估:英国卵巢癌筛查协作试验(UKCTOCS)的二次分析。
JAMA Oncol. 2018 Feb 1;4(2):190-195. doi: 10.1001/jamaoncol.2017.4211.
9
Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.卵巢癌筛查:美国预防服务工作组的更新证据报告和系统评价。
JAMA. 2018 Feb 13;319(6):595-606. doi: 10.1001/jama.2017.21421.
10
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.英国卵巢癌筛查协作试验(UKCTOCS)长期随访后的卵巢癌人群筛查和死亡率:一项随机对照试验。
Lancet. 2021 Jun 5;397(10290):2182-2193. doi: 10.1016/S0140-6736(21)00731-5. Epub 2021 May 12.

引用本文的文献

1
Few-Layer Graphene-Based Optical Nanobiosensors for the Early-Stage Detection of Ovarian Cancer Using Liquid Biopsy and an Active Learning Strategy.基于少层石墨烯的光学纳米生物传感器,用于通过液体活检和主动学习策略早期检测卵巢癌。
Cells. 2025 Mar 4;14(5):375. doi: 10.3390/cells14050375.
2
ReClassification of Patients with Ambiguous CA125 for Optimised Pre-Surgical Triage.对CA125不明确的患者进行重新分类以优化术前分诊。
Diagnostics (Basel). 2024 Mar 22;14(7):671. doi: 10.3390/diagnostics14070671.
3
Investigating harms of testing for ovarian cancer - psychological outcomes and cancer conversion rates in women with symptoms of ovarian cancer: A cohort study embedded in the multicentre ROCkeTS prospective diagnostic study.
调查卵巢癌检测的危害——卵巢癌症状女性的心理结果和癌症转化率:一项纳入多中心ROCkeTS前瞻性诊断研究的队列研究。
BJOG. 2024 Sep;131(10):1400-1410. doi: 10.1111/1471-0528.17813. Epub 2024 Mar 31.
4
Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.普通人群卵巢癌筛查的死亡率影响、风险及益处:英国卵巢癌筛查协作试验(UKCTOCS)随机对照试验
Health Technol Assess. 2025 May;29(10):1-93. doi: 10.3310/BHBR5832.
5
Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.卵巢癌筛查与诊断的当前及新兴方法:全面综述
Cancers (Basel). 2022 Jun 11;14(12):2885. doi: 10.3390/cancers14122885.
6
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.GOG-0199 研究:NRG 肿瘤学/妇科肿瘤学协会对接受预防性输卵管卵巢切除术或卵巢癌筛查的参与者进行前瞻性随访,以评估生活质量。
Gynecol Oncol. 2020 Jan;156(1):131-139. doi: 10.1016/j.ygyno.2019.10.026. Epub 2019 Nov 21.
7
Novel Approaches to Ovarian Cancer Screening.卵巢癌筛查的新方法。
Curr Oncol Rep. 2019 Jul 26;21(8):75. doi: 10.1007/s11912-019-0816-0.
8
Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis.参与 UKCTOCS 的 4418 名绝经后女性的性功能:定性自由文本分析。
Menopause. 2019 Oct;26(10):1100-1109. doi: 10.1097/GME.0000000000001377.
9
PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.PMS2 种系突变 c.943C>T(p.Arg315*) 导致的林奇综合征相关卵巢癌。
Mol Genet Genomic Med. 2019 Jun;7(6):e721. doi: 10.1002/mgg3.721. Epub 2019 May 5.
10
Screening for Ovarian Cancer: An Update.卵巢癌筛查:最新进展
J Midlife Health. 2019 Jan-Mar;10(1):3-5. doi: 10.4103/jmh.JMH_46_19.